The US Food and Drug Administration (FDA) does not have an overview of when Novo Nordisk will be able to meet full demand for weight loss drug Wegovy in the US, Reuters reports.

This was stated in the FDA’s list of medicines on backorder.

Here, the FDA writes about Wegovy doses of 0.25 milligrams, 0.5 milligrams, and 1.0 milligrams that access to the doses is limited and that the duration of the shortage of the doses is ”TBD,” meaning ”to be decided,” or can only be decided later.

The wording has changed from a previous assessment that stated the shortage will be resolved by September.

The FDA’s wording is in line with the announcements made by Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, at the presentation of the half-year results in August.

Back then, Fruergaard announced that Novo Nordisk will continue to reduce access to starting doses of Wegovy in the US market in the coming quarters.

Previously, Novo Nordisk signaled that the restrictions on access to starting doses only ran through September.

Novo Nordisk has imposed restrictions on low starting dosages to manage demand and ensure that those who start treatment can continue treatment.

According to the FDA, the high doses of Wegovy of 1.7 milligrams and 2.4 milligrams are readily available.